Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ina Oehme

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Redox Biology|October 8, 2018
The enzyme activity of histone deacetylase 8 is modulated by a redox-switchNiklas Jänsch, Christian Meyners, Marius Muth, et al.
International Journal of Cancer|October 2, 2012
HDAC11 is a novel drug target in carcinomasHedwig E Deubzer, Marie C Schier, Ina Oehme, et al.
Journal of Medicinal Chemistry|December 15, 2015
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) InhibitorsJohanna Senger, Jelena Melesina, Martin Marek, et al.
Future Medicinal Chemistry|August 31, 2016
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseasesAlokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, et al.
Trends in Pharmacological Sciences|May 28, 2015
HDAC8: a multifaceted target for therapeutic interventionsAlokta Chakrabarti, Ina Oehme, Olaf Witt, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 18, 2022
Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting ChimerasSalma Darwish, Tino Heimburg, Johannes Ridinger, et al.
FEBS Open Bio|June 26, 2025
Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell linesTharsagini V Nanthaprakash, Campbell W Gourlay, Ina Oehme, et al.
BMC Cancer|June 12, 2012
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancerDmitriy I Dovzhanskiy, Stefanie M Arnold, Thilo Hackert, et al.
Blood|June 27, 2013
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cellsNathalie Fiegler, Sonja Textor, Annette Arnold, et al.
European Journal of Medicinal Chemistry|October 21, 2019
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitorsBenjamin Wolff, Niklas Jänsch, Wisely Oki Sugiarto, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Redox Biology|October 8, 2018
The enzyme activity of histone deacetylase 8 is modulated by a redox-switchNiklas Jänsch, Christian Meyners, Marius Muth, et al.
International Journal of Cancer|October 2, 2012
HDAC11 is a novel drug target in carcinomasHedwig E Deubzer, Marie C Schier, Ina Oehme, et al.
Journal of Medicinal Chemistry|December 15, 2015
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) InhibitorsJohanna Senger, Jelena Melesina, Martin Marek, et al.
Future Medicinal Chemistry|August 31, 2016
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseasesAlokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, et al.
Trends in Pharmacological Sciences|May 28, 2015
HDAC8: a multifaceted target for therapeutic interventionsAlokta Chakrabarti, Ina Oehme, Olaf Witt, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 18, 2022
Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting ChimerasSalma Darwish, Tino Heimburg, Johannes Ridinger, et al.
FEBS Open Bio|June 26, 2025
Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell linesTharsagini V Nanthaprakash, Campbell W Gourlay, Ina Oehme, et al.
BMC Cancer|June 12, 2012
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancerDmitriy I Dovzhanskiy, Stefanie M Arnold, Thilo Hackert, et al.
Blood|June 27, 2013
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cellsNathalie Fiegler, Sonja Textor, Annette Arnold, et al.
European Journal of Medicinal Chemistry|October 21, 2019
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitorsBenjamin Wolff, Niklas Jänsch, Wisely Oki Sugiarto, et al.
Pageof 9